Evidence map›Paper›PMID 39574037›Full record

ArticleBMC cancer2024

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R Overbeck, Enriqueta Felip and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Armando SantoroDepartment of Biomedical Sciences, Humanitas University, Milan, Italy. armando.santoro@cancercenter.humanitas.it.
Garrido PilarDepartment of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain.
Daniel S W TanDepartment of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
Jon ZugazagoitiaDepartment of Medical Oncology, University Hospital, 12 de Octubre, Madrid, Spain.
Frances A ShepherdDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Alessandra BearzDepartment of Medical Oncology, Centro Di Riferimento Oncologico - CRO, Aviano, Italy.
Fabrice BarlesiDepartment of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP, Marseille, France.
Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Tobias R OverbeckDepartment of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Enriqueta FelipDepartment of Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Can CaiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Simantini EddyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Tracey McCullochNovartis Pharma AG, Basel, Switzerland.
Eric S SchaeferDepartment of Medical Oncology, Highlands Oncology Group, Fayetteville, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39574037
PMCPMC11580551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.